C4 Therapeutics, Inc. (CCCC) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$115.22M | +3.7% |
| 2024 | -$119.61M | +14.0% |
| 2023 | -$139.03M | -7.3% |
| 2022 | -$129.53M | -57.7% |
| 2021 | -$82.13M | -35.9% |
| 2020 | -$60.45M | -70.5% |
| 2019 | -$35.45M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$115.22M | +3.7% |
| 2024 | -$119.61M | +14.0% |
| 2023 | -$139.03M | -7.3% |
| 2022 | -$129.53M | -57.7% |
| 2021 | -$82.13M | -35.9% |
| 2020 | -$60.45M | -70.5% |
| 2019 | -$35.45M | — |